Personalized antiplatelet therapy for coronary artery disease patients: is this the future?

References

• Schatz RA, Baim DS, Leon M et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation83, 148–161 (1991).
   PubMed Web of Science ®Google Scholar
• Schömig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med.334, 1084–1089 (1996).
   PubMed Web of Science ®Google Scholar
• Moussa I, Oetgen M, Roubin G et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation99, 2364–2366 (1999).
   PubMed Web of Science ®Google Scholar
• CURE Investigators. Clopidogrel in Unstable angina to prevent Recurrent Events trial Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet358, 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug ‘resistance’. Part 1: mechanisms and clinical measurements. Nat. Rev. Cardiol.6, 273–282 (2009).
   PubMed Web of Science ®Google Scholar
• Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation108, 1682–1687 (2003).
   PubMed Web of Science ®Google Scholar
• Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol.45, 1157–1164 (2005).
   PubMed Web of Science ®Google Scholar
• Hollopeter G, Jantzen HM, Vincent D et al. Identification of platelet ADP receptor targeted by antithrombotic drugs. Nature409, 202–207 (2001).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Becker RC, Mann KG et al. Platelet function monitoring in patients with coronary artery disease. J. Am. Coll. Cardiol.50, 1822–1834 (2007).
   PubMed Web of Science ®Google Scholar
• Paniccia R, Antonucci E, Maggini N et al. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am. J. Clin. Pathol.131, 834–842 (2009).
   PubMed Web of Science ®Google Scholar
• Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am. J. Cardiol.104, 227–233 (2009).
   PubMed Web of Science ®Google Scholar
• Patti G, Nusca A, Mangiacapra F et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J. Am. Coll. Cardiol.52, 1128–1133 (2008).
   PubMed Web of Science ®Google Scholar
• Labarthe B, Theroux P, Angioi M et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J. Am. Coll. Cardiol.46, 638–645 (2005).
   PubMed Web of Science ®Google Scholar
• Morel O, Viellard C, Faure A et al. Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation. Ann. Cardiol. Angeiol.56, 21–29 (2007).
   PubMedGoogle Scholar
• Gurbel PA, Bliden KP, Hiatt BL et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation107, 2908–2913 (2003).
   PubMed Web of Science ®Google Scholar
• Geisler T, Kapp M, Göhring-Frischholz K et al. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart94, 743–747 (2008).
   PubMed Web of Science ®Google Scholar
• Paniccia R, Antonucci E, Gori AM et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J. Thromb. Haemost.5, 1839–1847 (2007).
   PubMed Web of Science ®Google Scholar
• Aleil B, Ravanat C, Cazenave JP et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with thrombotic cardiovascular diseases. J. Thromb. Haemost.3, 85–92 (2005).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Zaman KA et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation111, 1153–1159 (2005).
   PubMed Web of Science ®Google Scholar
• ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol.48, 931–938 (2006).
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Frundi D et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation111, 2560–2564 (2005).
   PubMed Web of Science ®Google Scholar
• Järemo P, Lindahl TL, Fransson SG et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J. Intern. Med.252, 233–238 (2002).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hayes KM et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol.45, 1392–1396 (2005).
   PubMed Web of Science ®Google Scholar
• Samara WM, Bliden KP, Tantry US et al. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb. Res.115, 89–94 (2005).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Clopidogrel resistance ? Thromb. Res.120, 311–321 (2007).
   PubMed Web of Science ®Google Scholar
• Roden DM, Stein CM. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation119, 2127–2130 (2009).
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J. Am. Coll. Cardiol.51, 256–260 (2008).
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Lang I, Christ G et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J. Am. Coll. Cardiol.52, 1557–1563 (2008).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360, 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA302, 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Barragan P, Bouvier JL, Roquebert PO et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc. Interv.59, 295–302 (2003).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Samara W et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J. Am. Coll. Cardiol.46, 1827–1832 (2005).
   PubMed Web of Science ®Google Scholar
• Buonamici P, Marcucci R, Migliorini A et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol.49, 2312–2317 (2007).
   PubMed Web of Science ®Google Scholar
• Blindt R, Stellbrink K, de Taeye A et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb. Haemost.98, 1329–1334 (2007).
   PubMed Web of Science ®Google Scholar
• Price MJ, Endemann S, Gollapudi RR et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J.29, 992–1000 (2008).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Guyer K et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POSTSTENTING study. J. Am. Coll. Cardiol.46, 1820–1826 (2005).
   PubMed Web of Science ®Google Scholar
• Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J. Am. Coll. Cardiol.49, 657–666 (2007).
   PubMed Web of Science ®Google Scholar
• Bonello L, Paganelli F, Arpin-Bornet M et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J. Thromb. Haemost.5, 1630–1636 (2007).
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Quilici J et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb. Haemost.98, 838–843 (2007).
   PubMed Web of Science ®Google Scholar
• von Beckerath N, Taubert D, Pogatsa-Murray G et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation112, 2946–2950 (2005).
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation119, 237–242 (2009).
   PubMed Web of Science ®Google Scholar
• Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation109, 3171–3175 (2004).
   PubMed Web of Science ®Google Scholar
• Patti G, Colonna G, Pasceri V et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation111, 2099–2106 (2005).
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol.48, 1339–1345 (2006).
   PubMed Web of Science ®Google Scholar
• Mehta S et al. randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: Results of the CURRENT OASIS 7 Trial. Presented at: ESC Congress, Barcelona, Spain 2009.
   Google Scholar
• Collet JP, Silvain J, Landivier A et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation118, 1225–1233 (2008).
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to VASP phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicentre randomized prospective study. J. Am. Coll. Cardiol.51, 1404–1411 (2008).
   PubMed Web of Science ®Google Scholar
• von Beckerath N, Kastrati A, Wieczorek A et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur. Heart J.28, 1814–1819 (2007).
   PubMed Web of Science ®Google Scholar
• Lemesle G, Delhaye C, Sudre A et al. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. Am. Heart J.157, 375–382 (2009).
   PubMed Web of Science ®Google Scholar
• Husted S, Emanuelsson H, Heptinstall S et al. G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J.27, 1038–1047 (2006).
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Grines CL, Bittl JA et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, Phase II, multicenter, randomized, placebo- and active-controlled trial. Am. Heart J.151, 689.e1–689.e10 (2006).
   PubMed Web of Science ®Google Scholar
• PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 trial. Circulation116, 2923–2932 (2007).
   PubMed Web of Science ®Google Scholar
• TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357, 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J.30, 1753–1763 (2009).
   PubMed Web of Science ®Google Scholar
• Cuisset T, Cayla G, Frere C et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from anti-platelet resistance to bleeding risk assessment? EuroIntervention5, 325–329 (2009).
   PubMed Web of Science ®Google Scholar
• PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.361, 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Siddique A, Butt M, Shantsila E et al. New antiplatelet drugs: beyond aspirin and clopidogrel. Int. J. Clin. Pract.63, 776–789 (2009).
   PubMed Web of Science ®Google Scholar